Dr Mark Lythgoe

Early-onset cancers (<50 yrs) are rising globally, linked to early-life exposures like diet, lifestyle, & microbiome changes. Awareness & dedicated studies are crucial. #Cancer #EarlyOnsetCancer #Oncology @oncoalert.bsky.social
rdcu.be/d49Ol

The evolving posology and administration of immune checkpoint inhibitors: subcutaneous formulations Immune checkpoint inhibitors (ICIs) have transformed cancer care. Recently, atezolizumab gained its first global approval in a subcutaneous (SC) formulation by the UK medicines regulator, being notable as the first time an FDA- and/or European Medicines Agency (EMA)-approved ICI has been licensed via this administration route. Here, we discuss this approval, other SC ICIs in development, and the benefits and challenges of this administration route, including potential implications for patient care.

Our thoughts on the evolving #posology of #Immunecheckpointinhibitors in
@trends in #Cancer

www.cell.com/trends/cance...

#Subcutaneous nivolumab approved by
@fda.gov across all indications - follows approval of SC atezolizumab in Sept 2024.

Will this be the preferred route of administration or will this suppress the development of new biosimilars?

@oncodaily.bsky.social @hemoncwarner.bsky.social

Scientists, academics, researchers: We’re excited to share that @altmetric.com is now tracking mentions of your research on Bluesky! 🧪

Wow #bluesky added to #altrimetric scores!

Early versus deferred use of CDK4/6 inhibitors in advanced breast cancer - Nature The phase 3 SONIA trial challenges the benefits of using cyclin-dependent kinase 4 and 6 inhibitors as a first-line compared with second-line treatment.

Hugely interesting paper in
#nature
about #SONIA trial challenging frontline CDK4/6 use in #breastcancer - does this have implications for practice today?

www.nature.com/articles/s41...

How to Keep Up With Molecular Testing and Targeted Therapies in Lung Cancer | JCO Oncology Practice Until the early 2000s, advanced or metastatic non–small cell lung cancer (NSCLC) was treated as a single disease with all histologic subtypes treated alike with standard chemotherapy agents. Over the ...

How to Keep Up With Molecular Testing and Targeted Therapies in Lung Cancer | JCO Oncology Practice ascopubs.org/doi/10.1200/... #LCSM

The World Health Organization notes 300 essential drugs are now in shortage.

What's behind the problems and what are countries doing about it?
www.bmj.com/content/387/...